| pubmed-article:9836109 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9836109 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:9836109 | lifeskim:mentions | umls-concept:C0021747 | lld:lifeskim |
| pubmed-article:9836109 | lifeskim:mentions | umls-concept:C0524910 | lld:lifeskim |
| pubmed-article:9836109 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:9836109 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:9836109 | lifeskim:mentions | umls-concept:C1623038 | lld:lifeskim |
| pubmed-article:9836109 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:9836109 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:9836109 | lifeskim:mentions | umls-concept:C0444956 | lld:lifeskim |
| pubmed-article:9836109 | lifeskim:mentions | umls-concept:C2003941 | lld:lifeskim |
| pubmed-article:9836109 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:9836109 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:9836109 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:9836109 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:9836109 | pubmed:dateCreated | 1999-2-11 | lld:pubmed |
| pubmed-article:9836109 | pubmed:abstractText | The long-term response to alpha-Interferon in HCV-related chronic liver diseases is disappointing. A randomized controlled trial was conducted to investigate: 1) if doubling the standard regimen of 3 MU recombinant alpha 2b-interferon thrice weekly for one year could improve the long-term response, and 2) the efficacy of these two schedules in cirrhotic patients. | lld:pubmed |
| pubmed-article:9836109 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9836109 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9836109 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9836109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9836109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9836109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9836109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9836109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9836109 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9836109 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:9836109 | pubmed:issn | 1125-8055 | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:MannoM LML | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:CanestriniCC | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:LongoGG | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:De LucaMM | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:AscioneAA | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:AddariiFF | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:RoccaFF | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:RaimondoGG | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:BullT BTB | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:GigliottiTT | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:AmitranoLL | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:Di... | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:ForteG BGB | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:TillmannH LHL | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:BicegliaOO | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:FaleoDD | lld:pubmed |
| pubmed-article:9836109 | pubmed:author | pubmed-author:VinelliFF | lld:pubmed |
| pubmed-article:9836109 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9836109 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:9836109 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9836109 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9836109 | pubmed:pagination | 517-23 | lld:pubmed |
| pubmed-article:9836109 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:meshHeading | pubmed-meshheading:9836109-... | lld:pubmed |
| pubmed-article:9836109 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9836109 | pubmed:articleTitle | Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study. | lld:pubmed |
| pubmed-article:9836109 | pubmed:affiliation | Liver Pathophysiology Unit, A. Cardarelli Hospital, Napoli, Italy. | lld:pubmed |
| pubmed-article:9836109 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9836109 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9836109 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:9836109 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9836109 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9836109 | lld:pubmed |
